首页 > 最新文献

Birth defects research. Part B, Developmental and reproductive toxicology最新文献

英文 中文
Mechanism of Developmental Effects in Rats Caused by an N-Phenylimide Herbicide: Transient Fetal Anemia and Sequelae during Mid-to-Late Gestation. n -苯基亚胺除草剂对大鼠发育影响的机制:妊娠中后期短暂性胎儿贫血和后遗症。
Q Environmental Science Pub Date : 2016-02-01 DOI: 10.1002/bdrb.21172
S. Kawamura, T. Yoshioka, N. Mito, N. Kishimoto, M. Nakaoka, A. Fantel
BACKGROUNDRat developmental toxicity including embryolethality and teratogenicity (mainly ventricular septal defects [VSDs] and wavy ribs) was produced by an N-phenylimide herbicide that inhibits protoporphyrinogen oxidase (PPO) common to chlorophyll and heme biosynthesis. Major characteristics of the developmental toxicity included species difference between rats and rabbits, compound-specific difference among structurally similar herbicides, and sensitive period. Protoporphyrin accumulation in treated fetuses closely correlated with the major characteristics. Iron deposits in erythroblastic mitochondria and degeneration of erythroblasts were observed in treated rat fetuses. In this study we investigated fetal anemia and subsequent developmental effects in rats, and inhibition of PPO in rats, rabbits, and humans by the herbicides in vitro.METHODSFetuses were treated on gestational day (GD) 12 and removed on GDs 13 through 20. All litters were examined externally. One half of litters were examined for blood and skeletal development, and the other half for interventricular foramen closure. Effects on PPO were determined in mitochondria from embryos and adult livers.RESULTSFetal anemia in rats was evident on GDs 13 through 16. Subsequently, enlarged heart, delayed closure of the foramen, reduced serum protein, and retarded rib ossification were observed. In vitro PPO inhibition exhibited species- and compound-specific differences corresponding to the developmental toxicity.CONCLUSIONWe propose that developmental toxicity results from PPO inhibition in primitive erythroblasts, causing transient fetal anemia followed by death. Compensatory enlargement of the fetal heart results in failure of interventricular foramen closure and VSD. Reduced serum protein leads to delayed ossification and wavy ribs.
n -苯基亚胺除草剂可抑制叶绿素和血红素生物合成中常见的原卟啉原氧化酶(PPO),从而产生包括胚胎致死性和致畸性(主要是室间隔缺损[VSDs]和波纹肋)的发育毒性。发育毒性的主要特征包括大鼠和家兔的种间差异、结构相似除草剂间化合物特异性差异和敏感期。原卟啉在治疗胎儿中的积累与主要特征密切相关。在处理后的大鼠胎儿中观察到红细胞线粒体中的铁沉积和红细胞变性。在本研究中,我们研究了大鼠胎儿贫血及其对发育的影响,以及除草剂对大鼠、兔和人体内PPO的抑制作用。方法在妊娠第12天对胎儿进行治疗,在妊娠第13 ~ 20天切除胎儿。所有幼崽都进行了外部检查。其中一半进行了血液和骨骼发育检查,另一半进行了室间孔闭合检查。测定了胚胎和成人肝脏线粒体对PPO的影响。结果大鼠胎儿贫血在GDs 13 ~ 16明显。随后,观察到心脏增大,孔关闭延迟,血清蛋白降低,肋骨骨化迟缓。体外PPO抑制表现出与发育毒性相对应的物种和化合物特异性差异。结论:发育毒性是由于原始红母细胞PPO受到抑制,导致胎儿短暂性贫血并死亡。胎儿心脏代偿性增大导致室间隔孔闭合失败和室间隔缺损。血清蛋白降低导致骨化延迟,肋骨呈波浪状。
{"title":"Mechanism of Developmental Effects in Rats Caused by an N-Phenylimide Herbicide: Transient Fetal Anemia and Sequelae during Mid-to-Late Gestation.","authors":"S. Kawamura, T. Yoshioka, N. Mito, N. Kishimoto, M. Nakaoka, A. Fantel","doi":"10.1002/bdrb.21172","DOIUrl":"https://doi.org/10.1002/bdrb.21172","url":null,"abstract":"BACKGROUND\u0000Rat developmental toxicity including embryolethality and teratogenicity (mainly ventricular septal defects [VSDs] and wavy ribs) was produced by an N-phenylimide herbicide that inhibits protoporphyrinogen oxidase (PPO) common to chlorophyll and heme biosynthesis. Major characteristics of the developmental toxicity included species difference between rats and rabbits, compound-specific difference among structurally similar herbicides, and sensitive period. Protoporphyrin accumulation in treated fetuses closely correlated with the major characteristics. Iron deposits in erythroblastic mitochondria and degeneration of erythroblasts were observed in treated rat fetuses. In this study we investigated fetal anemia and subsequent developmental effects in rats, and inhibition of PPO in rats, rabbits, and humans by the herbicides in vitro.\u0000\u0000\u0000METHODS\u0000Fetuses were treated on gestational day (GD) 12 and removed on GDs 13 through 20. All litters were examined externally. One half of litters were examined for blood and skeletal development, and the other half for interventricular foramen closure. Effects on PPO were determined in mitochondria from embryos and adult livers.\u0000\u0000\u0000RESULTS\u0000Fetal anemia in rats was evident on GDs 13 through 16. Subsequently, enlarged heart, delayed closure of the foramen, reduced serum protein, and retarded rib ossification were observed. In vitro PPO inhibition exhibited species- and compound-specific differences corresponding to the developmental toxicity.\u0000\u0000\u0000CONCLUSION\u0000We propose that developmental toxicity results from PPO inhibition in primitive erythroblasts, causing transient fetal anemia followed by death. Compensatory enlargement of the fetal heart results in failure of interventricular foramen closure and VSD. Reduced serum protein leads to delayed ossification and wavy ribs.","PeriodicalId":9120,"journal":{"name":"Birth defects research. Part B, Developmental and reproductive toxicology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89829953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Investigation on Toxicity and Teratogenicity in Rats of a Retinoid-Polyamine Conjugate with Potent Anti-Inflammatory Properties. 具有强抗炎作用的类维甲酸-多胺偶联物对大鼠的毒性和致畸性研究。
Q Environmental Science Pub Date : 2016-02-01 DOI: 10.1002/bdrb.21170
Theodoros Petridis, D. Giannakopoulou, Vassiliki Stamatopoulou, K. Grafanaki, C. Kostopoulos, H. Papadaki, C. Malavaki, Nikos Karamanos, Stathianna Douroumi, D. Papachristou, George E. Magoulas, D. Papaioannou, D. Drainas
Previous studies have shown that N(1),N(12)-bis(all-trans-retinoyl)spermine (RASP), a retinoid analog, inhibits RNase P activity and angiogenesis in the chicken embryo chorioallantoic membrane, demonstrates anti-tumor activity on prostate cancer cells, and acts as anti-inflammatory agent, being more effective and less toxic than all-trans retinoic acid. In an attempt to further characterize the biological profile of RASP, we tested its effects on organ toxicity and teratogenicity by daily oral gavage of RASP at a level of 50 mg/Kg of body weight in two generations of rats. We found that this compound does not induce changes to the body growth, the appearance of physical features, and the animal's reflexes. Additionally, no substantial histopathological lesions were found in brain, heart, lung, thymus, liver, thyroid gland, adrenal gland, pituitary gland, kidneys, spleen, skin, femora, prostate, testis, epididymis, vagina, uterus, and ovaries of RASP-treated animals. These results suggest RASP, as a promising lead compound for the treatment of several dermatological disorders and certain cancer types, has apparently minimal toxic side-effects as revealed in this two-generation reproduction study in rats.
已有研究表明,类维甲酸类似物N(1),N(12)-二(全反式维甲酸)精胺(RASP)抑制鸡胚绒毛膜尿囊膜RNase P活性和血管生成,对前列腺癌细胞具有抗肿瘤活性,并具有抗炎作用,比全反式维甲酸更有效,毒性更小。为了进一步表征RASP的生物学特性,我们在两代大鼠中每天口服50 mg/Kg体重水平的RASP,测试了其对器官毒性和致畸性的影响。我们发现,这种化合物不会引起身体生长、身体特征和动物反应的变化。此外,经rasps处理的动物的脑、心、肺、胸腺、肝脏、甲状腺、肾上腺、垂体、肾脏、脾脏、皮肤、股骨、前列腺、睾丸、附睾、阴道、子宫和卵巢均未见明显的组织病理学病变。这些结果表明,RASP作为治疗几种皮肤病和某些癌症类型的有希望的先导化合物,在大鼠的两代繁殖研究中显示,它的毒副作用明显很小。
{"title":"Investigation on Toxicity and Teratogenicity in Rats of a Retinoid-Polyamine Conjugate with Potent Anti-Inflammatory Properties.","authors":"Theodoros Petridis, D. Giannakopoulou, Vassiliki Stamatopoulou, K. Grafanaki, C. Kostopoulos, H. Papadaki, C. Malavaki, Nikos Karamanos, Stathianna Douroumi, D. Papachristou, George E. Magoulas, D. Papaioannou, D. Drainas","doi":"10.1002/bdrb.21170","DOIUrl":"https://doi.org/10.1002/bdrb.21170","url":null,"abstract":"Previous studies have shown that N(1),N(12)-bis(all-trans-retinoyl)spermine (RASP), a retinoid analog, inhibits RNase P activity and angiogenesis in the chicken embryo chorioallantoic membrane, demonstrates anti-tumor activity on prostate cancer cells, and acts as anti-inflammatory agent, being more effective and less toxic than all-trans retinoic acid. In an attempt to further characterize the biological profile of RASP, we tested its effects on organ toxicity and teratogenicity by daily oral gavage of RASP at a level of 50 mg/Kg of body weight in two generations of rats. We found that this compound does not induce changes to the body growth, the appearance of physical features, and the animal's reflexes. Additionally, no substantial histopathological lesions were found in brain, heart, lung, thymus, liver, thyroid gland, adrenal gland, pituitary gland, kidneys, spleen, skin, femora, prostate, testis, epididymis, vagina, uterus, and ovaries of RASP-treated animals. These results suggest RASP, as a promising lead compound for the treatment of several dermatological disorders and certain cancer types, has apparently minimal toxic side-effects as revealed in this two-generation reproduction study in rats.","PeriodicalId":9120,"journal":{"name":"Birth defects research. Part B, Developmental and reproductive toxicology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87559070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Numeric Estimates of Teratogenic Severity from Embryo-Fetal Developmental Toxicity Studies. 胚胎-胎儿发育毒性研究中致畸严重程度的数值估计。
Q Environmental Science Pub Date : 2016-02-01 DOI: 10.1002/bdrb.21171
L. Wise
A developing organism exposed to a toxicant will have a response that ranges from none to severe (i.e., death or malformation). The response at a given dosage may be termed teratogenic (or developmental toxic) severity and is dependent on exposure conditions. Prenatal/embryo-fetal developmental (EFD) toxicity studies in rodents and rabbits are the most consistent and definitive assessments of teratogenic severity, and teratogenesis screening assays are best validated against their results. A formula is presented that estimates teratogenic severity for each group, including control, within an EFD study. The developmental components include embryonic/fetal death, malformations, variations, and mean fetal weight. The contribution of maternal toxicity is included with multiplication factors to adjust for the extent of mortality, maternal body weight change, and other parameters deemed important. The derivation of the formula to calculate teratogenic severity is described. Various EFD data sets from the literature are presented to highlight considerations to the calculation of the various components of the formula. Each score is compared to the concurrent control group to obtain a relative teratogenic severity. The limited studies presented suggest relative scores of two- to
暴露于有毒物质的发育中的生物体将产生从无到严重(即死亡或畸形)的反应。在给定剂量下的反应可能被称为致畸(或发育毒性)严重程度,并取决于暴露条件。在啮齿动物和兔子中进行的产前/胚胎-胎儿发育(EFD)毒性研究是对致畸严重程度的最一致和最明确的评估,而致畸筛选试验是根据其结果进行验证的最佳方法。一个公式提出了估计致畸严重程度的每一组,包括对照组,在一个EFD研究。发育成分包括胚胎/胎儿死亡、畸形、变异和平均胎儿体重。母体毒性的贡献包括乘法因子,以调整死亡率的程度,母体体重的变化,以及其他被认为重要的参数。描述了计算致畸严重程度公式的推导。从文献中提出了各种EFD数据集,以突出对公式的各个组成部分的计算的考虑。将每个评分与同期对照组进行比较,以获得相对致畸严重程度。有限的研究表明,相对评分高于对照组2至5倍的患者致畸严重程度可检测到,但水平较低,而相对评分高于对照组≥5倍的患者致畸程度越来越严重。这样的评分可能有助于完善基于暴露的验证列表的概念,以供筛选试验的支持者(Daston等人,2014)通过估计“阳性”暴露的严重程度,或在其他情况下通过定义LOAEL(最低观察到的不良反应水平)的严重程度来使用。
{"title":"Numeric Estimates of Teratogenic Severity from Embryo-Fetal Developmental Toxicity Studies.","authors":"L. Wise","doi":"10.1002/bdrb.21171","DOIUrl":"https://doi.org/10.1002/bdrb.21171","url":null,"abstract":"A developing organism exposed to a toxicant will have a response that ranges from none to severe (i.e., death or malformation). The response at a given dosage may be termed teratogenic (or developmental toxic) severity and is dependent on exposure conditions. Prenatal/embryo-fetal developmental (EFD) toxicity studies in rodents and rabbits are the most consistent and definitive assessments of teratogenic severity, and teratogenesis screening assays are best validated against their results. A formula is presented that estimates teratogenic severity for each group, including control, within an EFD study. The developmental components include embryonic/fetal death, malformations, variations, and mean fetal weight. The contribution of maternal toxicity is included with multiplication factors to adjust for the extent of mortality, maternal body weight change, and other parameters deemed important. The derivation of the formula to calculate teratogenic severity is described. Various EFD data sets from the literature are presented to highlight considerations to the calculation of the various components of the formula. Each score is compared to the concurrent control group to obtain a relative teratogenic severity. The limited studies presented suggest relative scores of two- to <fivefold higher than control have detectable but a low level of teratogenic severity, and scores ≥ fivefold higher than control have increasingly more severe teratogenicity. Such scores may help refine the concept of an exposure-based validation list for use by proponents of screening assays (Daston et al., 2014) by estimating the severity of \"positive\" exposures, or in other situations by defining the severity of a LOAEL (lowest observed adverse effect level).","PeriodicalId":9120,"journal":{"name":"Birth defects research. Part B, Developmental and reproductive toxicology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86892660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
A Developmental Toxicology Assay Platform for Screening Teratogenic Liability of Pharmaceutical Compounds. 药物致畸性筛选的发育毒理学分析平台。
Q Environmental Science Pub Date : 2016-01-05 DOI: 10.1002/bdrb.21168
K. Augustine-Rauch, Cindy Zhang, Julieta M. Panzica-Kelly
Increasing need for proactive safety optimization of pharmaceutical compounds has led to generation and/or refinement of in vitro developmental toxicology assays. Our laboratory has developed three in vitro developmental toxicology assays to assess teratogenic liability of pharmaceutical compounds. These assays included a mouse molecular embryonic stem cell assay (MESCA), a dechorionated zebrafish embryo culture (ZEC) assay, and a streamlined rat whole embryo culture (rWEC) assay. Individually, the assays presented good (73-82%) predictivity. However, it remains to be determined whether combining or tiering the assays could enhance performance. Seventy-three compounds representing a broad spectrum of pharmaceutical targets and chemistry were evaluated across the assays to generate testing strategies that optimized performance. The MESCA and ZEC assays were found to have two limitations: compound solubility and frequent misclassification of compounds with H1 receptor or GABAnergic activity. The streamlined rWEC assay was found to be a cost-effective stand-alone assay for supporting poorly soluble compounds and/or ones with H1 or GABAnergic activity. For all other compounds, a tiering strategy using the MESCA and ZEC assays additionally optimized throughput, cost, and minimized animal use. The tiered strategy resulted in improved performance achieving 88% overall predictivity and was comparable with 89% overall predictivity achieved with frequency analysis (final teratogenic classification made from most frequent teratogenic classification from each individual assay). Furthermore there were 21 compounds in the test set characterized as definitive or suspect human teratogens and the multiassay approach achieved 95 and 91% correct classification using the tiered or frequency screening approach, respectively.
对药物化合物的主动安全性优化的需求日益增加,导致了体外发育毒理学分析的产生和/或改进。我们的实验室已经开发了三种体外发育毒理学试验来评估药物化合物的致畸性。这些试验包括小鼠分子胚胎干细胞试验(MESCA)、去角质斑马鱼胚胎培养(ZEC)试验和流线型大鼠全胚胎培养(rWEC)试验。单项分析的预测能力较好(73-82%)。然而,合并或分层检测是否能提高性能仍有待确定。73种化合物代表了广泛的药物靶点和化学成分,通过分析来评估,以产生优化性能的测试策略。MESCA和ZEC检测发现有两个局限性:化合物溶解度和具有H1受体或GABAnergic活性的化合物的频繁错误分类。流线型rWEC检测被发现是一种具有成本效益的独立检测方法,用于支持难溶性化合物和/或具有H1或GABAnergic活性的化合物。对于所有其他化合物,使用MESCA和ZEC检测的分层策略进一步优化了吞吐量、成本和最小化动物使用。分层策略提高了性能,达到88%的总体预测性,与频率分析达到的89%的总体预测性相当(最终的致畸分类是根据每个单独分析中最常见的致畸分类得出的)。此外,在测试集中有21种化合物被确定为人类致畸物或疑似致畸物,多重分析方法分别采用分层或频率筛选方法实现了95%和91%的正确分类。
{"title":"A Developmental Toxicology Assay Platform for Screening Teratogenic Liability of Pharmaceutical Compounds.","authors":"K. Augustine-Rauch, Cindy Zhang, Julieta M. Panzica-Kelly","doi":"10.1002/bdrb.21168","DOIUrl":"https://doi.org/10.1002/bdrb.21168","url":null,"abstract":"Increasing need for proactive safety optimization of pharmaceutical compounds has led to generation and/or refinement of in vitro developmental toxicology assays. Our laboratory has developed three in vitro developmental toxicology assays to assess teratogenic liability of pharmaceutical compounds. These assays included a mouse molecular embryonic stem cell assay (MESCA), a dechorionated zebrafish embryo culture (ZEC) assay, and a streamlined rat whole embryo culture (rWEC) assay. Individually, the assays presented good (73-82%) predictivity. However, it remains to be determined whether combining or tiering the assays could enhance performance. Seventy-three compounds representing a broad spectrum of pharmaceutical targets and chemistry were evaluated across the assays to generate testing strategies that optimized performance. The MESCA and ZEC assays were found to have two limitations: compound solubility and frequent misclassification of compounds with H1 receptor or GABAnergic activity. The streamlined rWEC assay was found to be a cost-effective stand-alone assay for supporting poorly soluble compounds and/or ones with H1 or GABAnergic activity. For all other compounds, a tiering strategy using the MESCA and ZEC assays additionally optimized throughput, cost, and minimized animal use. The tiered strategy resulted in improved performance achieving 88% overall predictivity and was comparable with 89% overall predictivity achieved with frequency analysis (final teratogenic classification made from most frequent teratogenic classification from each individual assay). Furthermore there were 21 compounds in the test set characterized as definitive or suspect human teratogens and the multiassay approach achieved 95 and 91% correct classification using the tiered or frequency screening approach, respectively.","PeriodicalId":9120,"journal":{"name":"Birth defects research. Part B, Developmental and reproductive toxicology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81788609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 33
Visualizing Compound Distribution during Zebrafish Embryo Development: The Effects of Lipophilicity and DMSO 斑马鱼胚胎发育过程中化合物分布的可视化:亲脂性和DMSO的影响
Q Environmental Science Pub Date : 2015-12-11 DOI: 10.1002/bdrb.21166
Coco de Koning, Manon Beekhuijzen, Marysia Tobor-Kapłon, Selinda de Vries-Buitenweg, Dick Schoutsen, Nico Leeijen, Beppy van de Waart, Harry Emmen

The predictability of the zebrafish embryo model is highly influenced by internal exposure of the embryo/larva. As compound uptake is likely to be influenced by factors such as lipophilicity, solvent use, and chorion presence, this article focuses on investigating their effects on compound distribution within the zebrafish embryo. To visualize compound uptake and distribution, zebrafish embryos were exposed for 96 hr, starting at 4 hr postfertilization, to water-soluble dyes: Schiff's reagent (logP –4.63), Giemsa stain (logP –0.77), Van Gierson stain (logP 1.64), Cresyl fast violet (logP 3.5), Eosine Y (logP 4.8), Sudan III (logP 7.5), and Oil red O (logP 9.81), with and without 1% dimethyl-sulfoxide (DMSO). Three additional compounds were used to analytically determine the uptake and distribution: Acyclovir (logP –1.56), Zidovudine (logP 0.05), and Metoprolol Tartrate Salt (logP 1.8). Examinations were performed every 24 hr. Both methods (visualization and specific analysis) showed that exposure to higher logP values results in higher compound uptake. Specific analysis showed that for lipophilic compounds >90% of compound is taken up by the embryo. For hydrophilic compounds, >90% of compound within the complete egg could not be associated to embryo or chorion and is probably distributed into the perivitelline space. Overall, internal exposure analyses on at least two occasions (i.e., before and after hatching) is crucial for interpretation of zebrafish embryotoxicity data, especially for compounds with extreme logP values. DMSO did not affect exposure when examined with the visualization method, however, this method might be not sensitive enough to draw hard conclusions.

斑马鱼胚胎模型的可预测性受到胚胎/幼虫内部暴露的高度影响。由于化合物的摄取可能受到亲脂性、溶剂使用和绒毛膜存在等因素的影响,本文重点研究了它们对斑马鱼胚胎中化合物分布的影响。为了观察化合物的吸收和分布,从受精后4小时开始,将斑马鱼胚胎暴露于水溶性染料中96小时:希夫试剂(logP -4.63),吉姆萨染色(logP -0.77), Van Gierson染色(logP 1.64),甲酚耐洗紫(logP 3.5),伊红Y (logP 4.8),苏丹III (logP 7.5)和油红O (logP 9.81),有和没有1%二甲亚砜(DMSO)。另外三种化合物用于分析测定摄取和分布:阿昔洛韦(logP -1.56)、齐多夫定(logP 0.05)和酒石酸美托洛尔盐(logP 1.8)。每24小时检查一次。两种方法(可视化和特异性分析)都表明,暴露于较高的logP值会导致较高的化合物摄取。具体分析表明,对于亲脂化合物,90%的化合物被胚胎吸收。对于亲水化合物,完整卵内90%的化合物不可能与胚胎或绒毛膜相关,可能分布在卵泡周围空间。总的来说,至少两次(即孵化前和孵化后)的内部暴露分析对于解释斑马鱼胚胎毒性数据至关重要,特别是对于具有极端logP值的化合物。当用可视化方法检查时,DMSO没有影响暴露,但是,这种方法可能不够灵敏,无法得出确切的结论。
{"title":"Visualizing Compound Distribution during Zebrafish Embryo Development: The Effects of Lipophilicity and DMSO","authors":"Coco de Koning,&nbsp;Manon Beekhuijzen,&nbsp;Marysia Tobor-Kapłon,&nbsp;Selinda de Vries-Buitenweg,&nbsp;Dick Schoutsen,&nbsp;Nico Leeijen,&nbsp;Beppy van de Waart,&nbsp;Harry Emmen","doi":"10.1002/bdrb.21166","DOIUrl":"https://doi.org/10.1002/bdrb.21166","url":null,"abstract":"<p>The predictability of the zebrafish embryo model is highly influenced by internal exposure of the embryo/larva. As compound uptake is likely to be influenced by factors such as lipophilicity, solvent use, and chorion presence, this article focuses on investigating their effects on compound distribution within the zebrafish embryo. To visualize compound uptake and distribution, zebrafish embryos were exposed for 96 hr, starting at 4 hr postfertilization, to water-soluble dyes: Schiff's reagent (logP –4.63), Giemsa stain (logP –0.77), Van Gierson stain (logP 1.64), Cresyl fast violet (logP 3.5), Eosine Y (logP 4.8), Sudan III (logP 7.5), and Oil red O (logP 9.81), with and without 1% dimethyl-sulfoxide (DMSO). Three additional compounds were used to analytically determine the uptake and distribution: Acyclovir (logP –1.56), Zidovudine (logP 0.05), and Metoprolol Tartrate Salt (logP 1.8). Examinations were performed every 24 hr. Both methods (visualization and specific analysis) showed that exposure to higher logP values results in higher compound uptake. Specific analysis showed that for lipophilic compounds &gt;90% of compound is taken up by the embryo. For hydrophilic compounds, &gt;90% of compound within the complete egg could not be associated to embryo or chorion and is probably distributed into the perivitelline space. Overall, internal exposure analyses on at least two occasions (i.e., before and after hatching) is crucial for interpretation of zebrafish embryotoxicity data, especially for compounds with extreme logP values. DMSO did not affect exposure when examined with the visualization method, however, this method might be not sensitive enough to draw hard conclusions.</p>","PeriodicalId":9120,"journal":{"name":"Birth defects research. Part B, Developmental and reproductive toxicology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/bdrb.21166","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91825217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 36
Advanced Paternal Age and Risk of Musculoskeletal Congenital Anomalies in Offspring 父亲高龄与后代肌肉骨骼先天性异常的风险
Q Environmental Science Pub Date : 2015-12-10 DOI: 10.1002/bdrb.21167
Stine Kjaer Urhoj, Laust Hvas Mortensen, Anne-Marie Nybo Andersen

OBJECTIVE

Previous research suggests that advanced paternal age increases the risk of musculoskeletal congenital anomalies (CAs) in offspring, but findings are inconsistent. This study aims to investigate the risk of musculoskeletal CAs according to paternal age at birth in an unselected population covering cohort of children.

STUDY DESIGN

A register-based prospective study of 1,605,885 children born in Denmark, 1978–2004, using information from record-linked health and administrative registers. The association between paternal age and overall musculoskeletal CAs, limb anomalies, craniosynostosis, skeletal dysplasias, syndromic musculoskeletal CAs, and other musculoskeletal CAs were investigated by multiple logistic regression analysis.

RESULTS

For overall musculoskeletal CAs, a slightly higher risk per 10-year increase in paternal age was found (odds ratio [OR] = 1.06 [95% CI: 1.01–1.11; where CI is confidence interval]). A 26% (95% CI: 2–56%) excess risk was found for fathers aged 50+ years compared to fathers aged 30–34 years. For syndromic musculoskeletal CAs, excess risks were found for fathers aged 40+ years, compared to fathers aged 30–34 years (40–44: OR = 1.38 [95% CI: 1.01–1.88], 45–49: OR = 1.45 [95% CI: 0.89–2.34], 50+: OR = 1.42 [95% CI: 0.73–2.79]). The risks in all other subgroups of musculoskeletal CAs were increased for fathers aged 50+ years.

CONCLUSIONS

A slightly higher risk for overall musculoskeletal CAs in offspring was found with increasing paternal age, mainly due to an excess risk of syndromic musculoskeletal CAs for fathers aged 40+ years. While associations between paternal age 50+ years and increased risk of all subtypes of musculoskeletal CAs were indicated, advanced paternal age likely plays a minor role in the etiology of these anomalies

先前的研究表明,父亲年龄大会增加后代发生肌肉骨骼先天性异常(CAs)的风险,但研究结果并不一致。本研究的目的是调查肌肉骨骼癌的风险根据父亲的出生年龄在一个未选择的人口覆盖队列的儿童。研究设计一项基于登记的前瞻性研究,研究对象为1978-2004年在丹麦出生的1,605,885名儿童,使用与记录相关的健康和行政登记信息。通过多元logistic回归分析,研究了父亲年龄与整体肌肉骨骼ca、肢体异常、颅缝闭锁、骨骼发育不良、综合征性肌肉骨骼ca和其他肌肉骨骼ca之间的关系。结果:对于整体肌肉骨骼ca,父亲年龄每增加10年,风险略高(优势比[OR] = 1.06 [95% CI: 1.01-1.11;其中CI为置信区间])。与30-34岁的父亲相比,50岁以上的父亲的风险高出26% (95% CI: 2-56%)。对于综合征型肌肉骨骼ca,与30-34岁的父亲相比,40岁以上的父亲风险更高(40 - 44岁:OR = 1.38 [95% CI: 1.01-1.88], 45-49岁:OR = 1.45 [95% CI: 0.89-2.34], 50岁以上:OR = 1.42 [95% CI: 0.73-2.79])。在50岁以上的父亲中,所有其他肌肉骨骼ca亚组的风险都增加了。结论:随着父亲年龄的增加,后代整体肌肉骨骼癌的风险略高,这主要是由于40岁以上父亲患综合征性肌肉骨骼癌的风险过高。虽然表明父亲年龄50岁以上与所有肌肉骨骼ca亚型风险增加之间存在关联,但父亲年龄较大可能在这些异常的病因学中起次要作用
{"title":"Advanced Paternal Age and Risk of Musculoskeletal Congenital Anomalies in Offspring","authors":"Stine Kjaer Urhoj,&nbsp;Laust Hvas Mortensen,&nbsp;Anne-Marie Nybo Andersen","doi":"10.1002/bdrb.21167","DOIUrl":"https://doi.org/10.1002/bdrb.21167","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> OBJECTIVE</h3>\u0000 \u0000 <p>Previous research suggests that advanced paternal age increases the risk of musculoskeletal congenital anomalies (CAs) in offspring, but findings are inconsistent. This study aims to investigate the risk of musculoskeletal CAs according to paternal age at birth in an unselected population covering cohort of children.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> STUDY DESIGN</h3>\u0000 \u0000 <p>A register-based prospective study of 1,605,885 children born in Denmark, 1978–2004, using information from record-linked health and administrative registers. The association between paternal age and overall musculoskeletal CAs, limb anomalies, craniosynostosis, skeletal dysplasias, syndromic musculoskeletal CAs, and other musculoskeletal CAs were investigated by multiple logistic regression analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> RESULTS</h3>\u0000 \u0000 <p>For overall musculoskeletal CAs, a slightly higher risk per 10-year increase in paternal age was found (odds ratio [OR] = 1.06 [95% CI: 1.01–1.11; where CI is confidence interval]). A 26% (95% CI: 2–56%) excess risk was found for fathers aged 50+ years compared to fathers aged 30–34 years. For syndromic musculoskeletal CAs, excess risks were found for fathers aged 40+ years, compared to fathers aged 30–34 years (40–44: OR = 1.38 [95% CI: 1.01–1.88], 45–49: OR = 1.45 [95% CI: 0.89–2.34], 50+: OR = 1.42 [95% CI: 0.73–2.79]). The risks in all other subgroups of musculoskeletal CAs were increased for fathers aged 50+ years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> CONCLUSIONS</h3>\u0000 \u0000 <p>A slightly higher risk for overall musculoskeletal CAs in offspring was found with increasing paternal age, mainly due to an excess risk of syndromic musculoskeletal CAs for fathers aged 40+ years. While associations between paternal age 50+ years and increased risk of all subtypes of musculoskeletal CAs were indicated, advanced paternal age likely plays a minor role in the etiology of these anomalies</p>\u0000 </section>\u0000 </div>","PeriodicalId":9120,"journal":{"name":"Birth defects research. Part B, Developmental and reproductive toxicology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/bdrb.21167","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91821656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Advanced Paternal Age and Risk of Musculoskeletal Congenital Anomalies in Offspring. 父亲高龄与后代肌肉骨骼先天性异常的风险。
Q Environmental Science Pub Date : 2015-12-01 DOI: 10.1002/bdrb.21167
S. K. Urhoj, L. Mortensen, A. Nybo Andersen
OBJECTIVEPrevious research suggests that advanced paternal age increases the risk of musculoskeletal congenital anomalies (CAs) in offspring, but findings are inconsistent. This study aims to investigate the risk of musculoskeletal CAs according to paternal age at birth in an unselected population covering cohort of children.STUDY DESIGNA register-based prospective study of 1,605,885 children born in Denmark, 1978-2004, using information from record-linked health and administrative registers. The association between paternal age and overall musculoskeletal CAs, limb anomalies, craniosynostosis, skeletal dysplasias, syndromic musculoskeletal CAs, and other musculoskeletal CAs were investigated by multiple logistic regression analysis.RESULTSFor overall musculoskeletal CAs, a slightly higher risk per 10-year increase in paternal age was found (odds ratio [OR] = 1.06 [95% CI: 1.01-1.11; where CI is confidence interval]). A 26% (95% CI: 2-56%) excess risk was found for fathers aged 50+ years compared to fathers aged 30-34 years. For syndromic musculoskeletal CAs, excess risks were found for fathers aged 40+ years, compared to fathers aged 30-34 years (40-44: OR = 1.38 [95% CI: 1.01-1.88], 45-49: OR = 1.45 [95% CI: 0.89-2.34], 50+: OR = 1.42 [95% CI: 0.73-2.79]). The risks in all other subgroups of musculoskeletal CAs were increased for fathers aged 50+ years.CONCLUSIONSA slightly higher risk for overall musculoskeletal CAs in offspring was found with increasing paternal age, mainly due to an excess risk of syndromic musculoskeletal CAs for fathers aged 40+ years. While associations between paternal age 50+ years and increased risk of all subtypes of musculoskeletal CAs were indicated, advanced paternal age likely plays a minor role in the etiology of these anomalies.
目的以往的研究表明,父亲年龄的增加会增加后代发生肌肉骨骼先天性异常(CAs)的风险,但研究结果并不一致。本研究的目的是调查肌肉骨骼癌的风险根据父亲的出生年龄在一个未选择的人口覆盖队列的儿童。研究设计一项基于登记的前瞻性研究,研究对象为1978-2004年在丹麦出生的1,605,885名儿童,使用与记录相关的健康和行政登记信息。通过多元logistic回归分析,研究了父亲年龄与整体肌肉骨骼ca、肢体异常、颅缝闭锁、骨骼发育不良、综合征性肌肉骨骼ca和其他肌肉骨骼ca之间的关系。结果对于整体肌肉骨骼类癌,父亲年龄每增加10年,风险略高(优势比[OR] = 1.06 [95% CI: 1.01-1.11;其中CI为置信区间])。与30-34岁的父亲相比,50岁以上的父亲的风险高出26% (95% CI: 2-56%)。对于综合征型肌肉骨骼ca,与30-34岁的父亲相比,40岁以上的父亲风险更高(40-44岁:OR = 1.38 [95% CI: 1.01-1.88], 45-49岁:OR = 1.45 [95% CI: 0.89-2.34], 50岁以上:OR = 1.42 [95% CI: 0.73-2.79])。在50岁以上的父亲中,所有其他肌肉骨骼ca亚组的风险都增加了。结论随着父亲年龄的增加,后代整体肌肉骨骼癌的风险略高,这主要是由于40岁以上父亲患综合征性肌肉骨骼癌的风险过高。虽然表明父亲年龄50岁以上与所有肌肉骨骼ca亚型风险增加之间存在关联,但父亲年龄较大可能在这些异常的病因学中起次要作用。
{"title":"Advanced Paternal Age and Risk of Musculoskeletal Congenital Anomalies in Offspring.","authors":"S. K. Urhoj, L. Mortensen, A. Nybo Andersen","doi":"10.1002/bdrb.21167","DOIUrl":"https://doi.org/10.1002/bdrb.21167","url":null,"abstract":"OBJECTIVE\u0000Previous research suggests that advanced paternal age increases the risk of musculoskeletal congenital anomalies (CAs) in offspring, but findings are inconsistent. This study aims to investigate the risk of musculoskeletal CAs according to paternal age at birth in an unselected population covering cohort of children.\u0000\u0000\u0000STUDY DESIGN\u0000A register-based prospective study of 1,605,885 children born in Denmark, 1978-2004, using information from record-linked health and administrative registers. The association between paternal age and overall musculoskeletal CAs, limb anomalies, craniosynostosis, skeletal dysplasias, syndromic musculoskeletal CAs, and other musculoskeletal CAs were investigated by multiple logistic regression analysis.\u0000\u0000\u0000RESULTS\u0000For overall musculoskeletal CAs, a slightly higher risk per 10-year increase in paternal age was found (odds ratio [OR] = 1.06 [95% CI: 1.01-1.11; where CI is confidence interval]). A 26% (95% CI: 2-56%) excess risk was found for fathers aged 50+ years compared to fathers aged 30-34 years. For syndromic musculoskeletal CAs, excess risks were found for fathers aged 40+ years, compared to fathers aged 30-34 years (40-44: OR = 1.38 [95% CI: 1.01-1.88], 45-49: OR = 1.45 [95% CI: 0.89-2.34], 50+: OR = 1.42 [95% CI: 0.73-2.79]). The risks in all other subgroups of musculoskeletal CAs were increased for fathers aged 50+ years.\u0000\u0000\u0000CONCLUSIONS\u0000A slightly higher risk for overall musculoskeletal CAs in offspring was found with increasing paternal age, mainly due to an excess risk of syndromic musculoskeletal CAs for fathers aged 40+ years. While associations between paternal age 50+ years and increased risk of all subtypes of musculoskeletal CAs were indicated, advanced paternal age likely plays a minor role in the etiology of these anomalies.","PeriodicalId":9120,"journal":{"name":"Birth defects research. Part B, Developmental and reproductive toxicology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84935235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Early Vaginal Opening in Juvenile Female Rats Given BRAF-Inhibitor Dabrafenib Is Not Associated with Early Physiologic Sexual Maturation. 给予braf抑制剂Dabrafenib的幼年雌性大鼠阴道早期开放与早期生理性性成熟无关。
Q Environmental Science Pub Date : 2015-12-01 DOI: 10.1002/bdrb.21165
L. Posobiec, J. Vidal, Angela Hughes-Earle, Susan B Laffan, T. Hart
Dabrafenib (DAB), an inhibitor of BRAF kinase activity, is approved for metastatic melanoma with a BRAF V600E mutation. In support of pediatric cancer development, a nonclinical juvenile rat toxicity study was conducted in which females had early vaginal opening (VO). It was hypothesized that the early VO was not indicative of sexual maturation, but a result of a local effect on the vagina. An investigative study was conducted that mimicked the definitive study design, with rats given DAB or vehicle orally from Postnatal Day (PND) 7 to 35 and with necropsy subsets just before VO, at the first and second estrus, along with age-matched controls. Histopathology was performed on reproductive tissues, including immunohistochemistry for BRAF expression. VO occurred earlier in DAB females than in controls (PND 27.2 vs. 31.5); however, the timing of the first estrus was unaffected (PND 34.0 vs. 33.0). DAB-treated females evaluated just before VO (PND 22.0) had mostly immature reproductive tracts with no evidence of ovulation, similar to age-matched controls; however, DAB-treated females had keratinized and histologically open vaginas. Also, there was raised skin around the urogenital area, which correlated with hyperplasia/keratosis of the vulvar skin and keratinization of the distal vagina. BRAF expression (evaluated in controls) was localized to these tissues. Thus, early VO in rats given DAB likely represents a local effect accelerating vaginal keratinization to become open and not accelerated sexual maturation.
Dabrafenib (DAB)是一种BRAF激酶活性抑制剂,被批准用于BRAF V600E突变的转移性黑色素瘤。为了支持儿童癌症的发展,进行了一项非临床幼年大鼠毒性研究,其中雌性早期阴道开口(VO)。据推测,早期的VO不是性成熟的标志,而是阴道局部作用的结果。一项模拟最终研究设计的调查研究进行了,从出生后第7天(PND)到35岁,大鼠口服DAB或载药,并在VO之前,在第一次和第二次发情,以及年龄匹配的对照组进行尸检。对生殖组织进行组织病理学检查,包括免疫组化检测BRAF表达。女性DAB患者比对照组更早发生VO (PND 27.2 vs. 31.5);然而,第一次发情的时间不受影响(PND 34.0 vs. 33.0)。在VO (PND 22.0)之前接受dada治疗的女性生殖道大多不成熟,没有排卵的证据,与年龄匹配的对照组相似;然而,接受dada治疗的女性阴道角化,组织学上开放。此外,泌尿生殖区周围有凸起的皮肤,这与外阴皮肤增生/角化病和阴道远端角化有关。BRAF表达(在对照组中评估)局限于这些组织。因此,给予DAB的大鼠早期VO可能代表了局部效应,加速阴道角化变得开放,而不是加速性成熟。
{"title":"Early Vaginal Opening in Juvenile Female Rats Given BRAF-Inhibitor Dabrafenib Is Not Associated with Early Physiologic Sexual Maturation.","authors":"L. Posobiec, J. Vidal, Angela Hughes-Earle, Susan B Laffan, T. Hart","doi":"10.1002/bdrb.21165","DOIUrl":"https://doi.org/10.1002/bdrb.21165","url":null,"abstract":"Dabrafenib (DAB), an inhibitor of BRAF kinase activity, is approved for metastatic melanoma with a BRAF V600E mutation. In support of pediatric cancer development, a nonclinical juvenile rat toxicity study was conducted in which females had early vaginal opening (VO). It was hypothesized that the early VO was not indicative of sexual maturation, but a result of a local effect on the vagina. An investigative study was conducted that mimicked the definitive study design, with rats given DAB or vehicle orally from Postnatal Day (PND) 7 to 35 and with necropsy subsets just before VO, at the first and second estrus, along with age-matched controls. Histopathology was performed on reproductive tissues, including immunohistochemistry for BRAF expression. VO occurred earlier in DAB females than in controls (PND 27.2 vs. 31.5); however, the timing of the first estrus was unaffected (PND 34.0 vs. 33.0). DAB-treated females evaluated just before VO (PND 22.0) had mostly immature reproductive tracts with no evidence of ovulation, similar to age-matched controls; however, DAB-treated females had keratinized and histologically open vaginas. Also, there was raised skin around the urogenital area, which correlated with hyperplasia/keratosis of the vulvar skin and keratinization of the distal vagina. BRAF expression (evaluated in controls) was localized to these tissues. Thus, early VO in rats given DAB likely represents a local effect accelerating vaginal keratinization to become open and not accelerated sexual maturation.","PeriodicalId":9120,"journal":{"name":"Birth defects research. Part B, Developmental and reproductive toxicology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84734104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Early Vaginal Opening in Juvenile Female Rats Given BRAF-Inhibitor Dabrafenib Is Not Associated with Early Physiologic Sexual Maturation 给予braf抑制剂Dabrafenib的幼年雌性大鼠阴道早期开放与早期生理性性成熟无关
Q Environmental Science Pub Date : 2015-12-01 DOI: 10.1002/bdrb.21165
Lorraine M. Posobiec, Justin D. Vidal, Angela Hughes-Earle, Susan B. Laffan, Timothy Hart

Dabrafenib (DAB), an inhibitor of BRAF kinase activity, is approved for metastatic melanoma with a BRAF V600E mutation. In support of pediatric cancer development, a nonclinical juvenile rat toxicity study was conducted in which females had early vaginal opening (VO). It was hypothesized that the early VO was not indicative of sexual maturation, but a result of a local effect on the vagina. An investigative study was conducted that mimicked the definitive study design, with rats given DAB or vehicle orally from Postnatal Day (PND) 7 to 35 and with necropsy subsets just before VO, at the first and second estrus, along with age-matched controls. Histopathology was performed on reproductive tissues, including immunohistochemistry for BRAF expression. VO occurred earlier in DAB females than in controls (PND 27.2 vs. 31.5); however, the timing of the first estrus was unaffected (PND 34.0 vs. 33.0). DAB-treated females evaluated just before VO (PND 22.0) had mostly immature reproductive tracts with no evidence of ovulation, similar to age-matched controls; however, DAB-treated females had keratinized and histologically open vaginas. Also, there was raised skin around the urogenital area, which correlated with hyperplasia/keratosis of the vulvar skin and keratinization of the distal vagina. BRAF expression (evaluated in controls) was localized to these tissues. Thus, early VO in rats given DAB likely represents a local effect accelerating vaginal keratinization to become open and not accelerated sexual maturation

Dabrafenib (DAB)是一种BRAF激酶活性抑制剂,被批准用于BRAF V600E突变的转移性黑色素瘤。为了支持儿童癌症的发展,进行了一项非临床幼年大鼠毒性研究,其中雌性早期阴道开口(VO)。据推测,早期的VO不是性成熟的标志,而是阴道局部作用的结果。一项模拟最终研究设计的调查研究进行了,从出生后第7天(PND)到35岁,大鼠口服DAB或载药,并在VO之前,在第一次和第二次发情,以及年龄匹配的对照组进行尸检。对生殖组织进行组织病理学检查,包括免疫组化检测BRAF表达。女性DAB患者比对照组更早发生VO (PND 27.2 vs. 31.5);然而,第一次发情的时间不受影响(PND 34.0 vs. 33.0)。在VO (PND 22.0)之前接受dada治疗的女性生殖道大多不成熟,没有排卵的证据,与年龄匹配的对照组相似;然而,接受dada治疗的女性阴道角化,组织学上开放。此外,泌尿生殖区周围有凸起的皮肤,这与外阴皮肤增生/角化病和阴道远端角化有关。BRAF表达(在对照组中评估)局限于这些组织。因此,给予DAB的大鼠早期VO可能代表了局部效应,加速阴道角化变得开放,而不是加速性成熟
{"title":"Early Vaginal Opening in Juvenile Female Rats Given BRAF-Inhibitor Dabrafenib Is Not Associated with Early Physiologic Sexual Maturation","authors":"Lorraine M. Posobiec,&nbsp;Justin D. Vidal,&nbsp;Angela Hughes-Earle,&nbsp;Susan B. Laffan,&nbsp;Timothy Hart","doi":"10.1002/bdrb.21165","DOIUrl":"https://doi.org/10.1002/bdrb.21165","url":null,"abstract":"<p>Dabrafenib (DAB), an inhibitor of BRAF kinase activity, is approved for metastatic melanoma with a BRAF V600E mutation. In support of pediatric cancer development, a nonclinical juvenile rat toxicity study was conducted in which females had early vaginal opening (VO). It was hypothesized that the early VO was not indicative of sexual maturation, but a result of a local effect on the vagina. An investigative study was conducted that mimicked the definitive study design, with rats given DAB or vehicle orally from Postnatal Day (PND) 7 to 35 and with necropsy subsets just before VO, at the first and second estrus, along with age-matched controls. Histopathology was performed on reproductive tissues, including immunohistochemistry for BRAF expression. VO occurred earlier in DAB females than in controls (PND 27.2 vs. 31.5); however, the timing of the first estrus was unaffected (PND 34.0 vs. 33.0). DAB-treated females evaluated just before VO (PND 22.0) had mostly immature reproductive tracts with no evidence of ovulation, similar to age-matched controls; however, DAB-treated females had keratinized and histologically open vaginas. Also, there was raised skin around the urogenital area, which correlated with hyperplasia/keratosis of the vulvar skin and keratinization of the distal vagina. BRAF expression (evaluated in controls) was localized to these tissues. Thus, early VO in rats given DAB likely represents a local effect accelerating vaginal keratinization to become open and not accelerated sexual maturation</p>","PeriodicalId":9120,"journal":{"name":"Birth defects research. Part B, Developmental and reproductive toxicology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/bdrb.21165","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91782069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Visualizing Compound Distribution during Zebrafish Embryo Development: The Effects of Lipophilicity and DMSO. 斑马鱼胚胎发育过程中化合物分布的可视化:亲脂性和DMSO的影响。
Q Environmental Science Pub Date : 2015-12-01 DOI: 10.1002/bdrb.21166
C. D. de Koning, M. Beekhuijzen, M. Tobor-Kapłon, Selinda de Vries-Buitenweg, Dick Schoutsen, Nico Leeijen, Beppy van de Waart, H. Emmen
The predictability of the zebrafish embryo model is highly influenced by internal exposure of the embryo/larva. As compound uptake is likely to be influenced by factors such as lipophilicity, solvent use, and chorion presence, this article focuses on investigating their effects on compound distribution within the zebrafish embryo. To visualize compound uptake and distribution, zebrafish embryos were exposed for 96 hr, starting at 4 hr postfertilization, to water-soluble dyes: Schiff's reagent (logP -4.63), Giemsa stain (logP -0.77), Van Gierson stain (logP 1.64), Cresyl fast violet (logP 3.5), Eosine Y (logP 4.8), Sudan III (logP 7.5), and Oil red O (logP 9.81), with and without 1% dimethyl-sulfoxide (DMSO). Three additional compounds were used to analytically determine the uptake and distribution: Acyclovir (logP -1.56), Zidovudine (logP 0.05), and Metoprolol Tartrate Salt (logP 1.8). Examinations were performed every 24 hr. Both methods (visualization and specific analysis) showed that exposure to higher logP values results in higher compound uptake. Specific analysis showed that for lipophilic compounds >90% of compound is taken up by the embryo. For hydrophilic compounds, >90% of compound within the complete egg could not be associated to embryo or chorion and is probably distributed into the perivitelline space. Overall, internal exposure analyses on at least two occasions (i.e., before and after hatching) is crucial for interpretation of zebrafish embryotoxicity data, especially for compounds with extreme logP values. DMSO did not affect exposure when examined with the visualization method, however, this method might be not sensitive enough to draw hard conclusions.
斑马鱼胚胎模型的可预测性受到胚胎/幼虫内部暴露的高度影响。由于化合物的摄取可能受到亲脂性、溶剂使用和绒毛膜存在等因素的影响,本文重点研究了它们对斑马鱼胚胎中化合物分布的影响。为了观察化合物的吸收和分布,从受精后4小时开始,将斑马鱼胚胎暴露于水溶性染料中96小时:希夫试剂(logP -4.63),吉姆萨染色(logP -0.77), Van Gierson染色(logP 1.64),甲酚耐洗紫(logP 3.5),伊红Y (logP 4.8),苏丹III (logP 7.5)和油红O (logP 9.81),有和没有1%二甲亚砜(DMSO)。另外三种化合物用于分析测定摄取和分布:阿昔洛韦(logP -1.56)、齐多夫定(logP 0.05)和酒石酸美托洛尔盐(logP 1.8)。每24小时检查一次。两种方法(可视化和特异性分析)都表明,暴露于较高的logP值会导致较高的化合物摄取。特异性分析表明,对于亲脂性化合物,90%以上的化合物被胚胎吸收。对于亲水化合物,完整卵内>90%的化合物不与胚胎或绒毛膜相关,可能分布在卵泡周围空间。总的来说,至少两次(即孵化前和孵化后)的内部暴露分析对于解释斑马鱼胚胎毒性数据至关重要,特别是对于具有极端logP值的化合物。当用可视化方法检查时,DMSO没有影响暴露,但是,这种方法可能不够灵敏,无法得出确切的结论。
{"title":"Visualizing Compound Distribution during Zebrafish Embryo Development: The Effects of Lipophilicity and DMSO.","authors":"C. D. de Koning, M. Beekhuijzen, M. Tobor-Kapłon, Selinda de Vries-Buitenweg, Dick Schoutsen, Nico Leeijen, Beppy van de Waart, H. Emmen","doi":"10.1002/bdrb.21166","DOIUrl":"https://doi.org/10.1002/bdrb.21166","url":null,"abstract":"The predictability of the zebrafish embryo model is highly influenced by internal exposure of the embryo/larva. As compound uptake is likely to be influenced by factors such as lipophilicity, solvent use, and chorion presence, this article focuses on investigating their effects on compound distribution within the zebrafish embryo. To visualize compound uptake and distribution, zebrafish embryos were exposed for 96 hr, starting at 4 hr postfertilization, to water-soluble dyes: Schiff's reagent (logP -4.63), Giemsa stain (logP -0.77), Van Gierson stain (logP 1.64), Cresyl fast violet (logP 3.5), Eosine Y (logP 4.8), Sudan III (logP 7.5), and Oil red O (logP 9.81), with and without 1% dimethyl-sulfoxide (DMSO). Three additional compounds were used to analytically determine the uptake and distribution: Acyclovir (logP -1.56), Zidovudine (logP 0.05), and Metoprolol Tartrate Salt (logP 1.8). Examinations were performed every 24 hr. Both methods (visualization and specific analysis) showed that exposure to higher logP values results in higher compound uptake. Specific analysis showed that for lipophilic compounds >90% of compound is taken up by the embryo. For hydrophilic compounds, >90% of compound within the complete egg could not be associated to embryo or chorion and is probably distributed into the perivitelline space. Overall, internal exposure analyses on at least two occasions (i.e., before and after hatching) is crucial for interpretation of zebrafish embryotoxicity data, especially for compounds with extreme logP values. DMSO did not affect exposure when examined with the visualization method, however, this method might be not sensitive enough to draw hard conclusions.","PeriodicalId":9120,"journal":{"name":"Birth defects research. Part B, Developmental and reproductive toxicology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73966284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 39
期刊
Birth defects research. Part B, Developmental and reproductive toxicology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1